Our finding that hypertension and DM may be effect modifiers on the association between CD14+CD16+ monocyte transmigration and cognition indicate that PWH on ART with these comorbidities could be a more vulnerable population that would most benefit from a therapy that limits CD14+CD16+ monocyte transmigration across the BBB. This evidence concerns the gene CD14 and hypertensive disorder.